Company intelligence / Profile preview
Covant Therapeutics
Boston, Massachusetts, United Statescovanttx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Covant Therapeutics is developing covalent therapeutics with two main programs currently in preclinical stage: an NRAS inhibitor for melanoma and an ADAR1 inhibitor for cancer treatment.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculescovalent therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Boehringer Ingelheim (March 2023, ADAR1 program)Enara Bio (January 2021, Dark Antigen™ platform)
Beyond the preview
Go deeper on Covant Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Covant Therapeutics.